Prime Medicine, Inc. (PRME) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Cambridge, MA, 美国. 現任CEO為 Allan Reine.
PRME 擁有 IPO日期為 2022-10-20, 214 名全職員工, 在 NASDAQ Global Market, 市值為 $684.29M.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
